This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Alfentanil

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Alfentanil is a synthetic opioid analgesic with a high potency and short duration of action. Like fentanil, it is useful for:

  • short operative analgesia, e.g. outpatient and day surgery
  • enhancement of general anaesthesia
  • suppression of spontaneous respiration in patients on assisted ventilation
  • cardiovascular surgery; it disrupts this system relatively little

The key side effect is that of severe respiratory depression.

Alfentanil - Seek specialist palliative care advice (1)

  • 1mg SC alfentanil = 10mg SC diamorphine = 30mg oral morphine = 15mg SC morphine

  • suitable parenteral opioid for use in advanced renal disease under specialist guidance. Alfentanil has a short duration of action which limits its use for breakthrough analgesia
  • note very different dose conversions than Fentanyl

  • alfentanil and Fentanyl are different drugs

Reference:

  • 1) West Midlands Palliative Care Physicians (2012). Palliative care - guidelines for the use of drugs in symptoms control.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.